Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer. Nozawa K, Sawaki M, Iwata H. Lancet Oncol 2023;24:e103.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nozawa K, Sawaki M, Iwata H. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer. Lancet Oncol 2023;24:e103.
PMID: 36858724